Scholarlink

Background <p>Resistance to poly ADP-ribose polymerase (PARP) inhibitors has emerged as a major obstacle to durable clinical benefit in breast cancer. While multiple preclinical strategies have been proposed, there is a lack of translational frameworks that prioritize interventions based on mechanistic robustness, biomarker relevance, and strength of evidence.</p> Methods <p>We performed a systematic and evidence-informed synthesis of 22 preclinical studies investigating therapeutic approaches to overcome PARP inhibitor resistance. Studies were evaluated across experimental models, mechanistic endpoints, and therapeutic outcomes. Risk of bias was assessed using the SYRCLE and ROBINS-I tools, and the consistency and certainty of evidence were appraised using the GRADE framework to support translational prioritization.</p> Results <p>Epigenetic targeting via <i>EZH2</i> inhibition and immune microenvironment modulation through STING pathway activation consistently demonstrated high-quality evidence for tumor suppression, survival benefit, and immunologic activation in <i>BRCA1</i>-mutant models. In contrast, strategies aimed at restoring homologous recombination exhibited strong in vitro synergy but limited in vivo translatability, underscoring pharmacokinetic and model-dependent constraints.</p> Conclusions <p>This review advances an evidence-based translational prioritization framework to guide the clinical development of combination strategies for PARP inhibitor–resistant breast cancer. We identify critical gaps in biomarker integration, standardized resistance modeling—particularly in <i>BRCA</i> wild-type disease–and dynamic monitoring of resistance evolution, and propose key directions for future preclinical and early-phase clinical research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Translational prioritization of strategies to overcome poly ADP-ribose polymerase inhibitor resistance in breast cancer based on systematic review of preclinical evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月24日

查看全文
  • Kezhen Shen,
  • Lei Cai

摘要

Background

Resistance to poly ADP-ribose polymerase (PARP) inhibitors has emerged as a major obstacle to durable clinical benefit in breast cancer. While multiple preclinical strategies have been proposed, there is a lack of translational frameworks that prioritize interventions based on mechanistic robustness, biomarker relevance, and strength of evidence.

Methods

We performed a systematic and evidence-informed synthesis of 22 preclinical studies investigating therapeutic approaches to overcome PARP inhibitor resistance. Studies were evaluated across experimental models, mechanistic endpoints, and therapeutic outcomes. Risk of bias was assessed using the SYRCLE and ROBINS-I tools, and the consistency and certainty of evidence were appraised using the GRADE framework to support translational prioritization.

Results

Epigenetic targeting via EZH2 inhibition and immune microenvironment modulation through STING pathway activation consistently demonstrated high-quality evidence for tumor suppression, survival benefit, and immunologic activation in BRCA1-mutant models. In contrast, strategies aimed at restoring homologous recombination exhibited strong in vitro synergy but limited in vivo translatability, underscoring pharmacokinetic and model-dependent constraints.

Conclusions

This review advances an evidence-based translational prioritization framework to guide the clinical development of combination strategies for PARP inhibitor–resistant breast cancer. We identify critical gaps in biomarker integration, standardized resistance modeling—particularly in BRCA wild-type disease–and dynamic monitoring of resistance evolution, and propose key directions for future preclinical and early-phase clinical research.